ReviewFrontiers in pharmacology2026
Energy metabolic dysregulation in heat stroke: from mitochondrial dysfunction to multi-organ failure mechanisms and targeted intervention.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heat stroke (HS) is a life-threatening acute condition characterized by hyperthermia, central nervous system dysfunction, and multiple organ failure. Energy metabolism disruption serves as a pivotal link between hyperthermia and multi-organ injury. This review synthesizes current evidence on the mechanisms of energy metabolism dysregulation in HS and evaluates emerging intervention strategies. Mitochondrial dysfunction-manifested as structural damage, oxidative phosphorylation impairment, and excessive fission-represents an initiating event. This is followed by glucose-lipid metabolic restructuring, impaired substrate utilization, and energy depletion. These metabolic derangements mediate secondary injury in the intestine (barrier disruption and endotoxemia), brain (hypothalamic dysregulation), and lung (oxidative stress and barrier leakage). Intervention strategies are categorized into mitochondrial protection (e.g., astragaloside IV, curcumin), mitophagy modulation (e.g., melatonin, rapamycin), and substrate metabolism regulation (e.g., taurine, acetyl-L-carnitine). Notably, most current evidence for these interventions is derived from preclinical studies, and HS-validated human studies are still needed to confirm their efficacy and safety. While these approaches show promise in preclinical models, translational gaps remain, including limited validation in HS-specific models, lack of biomarker-guided patient stratification, and insufficient data on vulnerable populations. Future priorities include dynamic metabolic monitoring, identification of early-warning biomarkers, and development of personalized interventions tailored to age, comorbidity status, and metabolic phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.